Search | Clinical Trials Finder

Conditions: Advanced Solid Tumors
Interventions: AMG 355, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more

Conditions: Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Interventions: cabozantinib; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Kidney Cancer, Lung Cancer
Interventions: interleukin-4 PE38KDEL cytotoxin; Biological
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 2
States / cities: Tucson, Arizona • Los Angeles, California

Conditions: Malignant Pleural Mesothelioma (MPM)
Interventions: cyclophosphamide, CAR T cells; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: Autologous Blood Patch, Standard of Care (per Physician); Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer
Interventions: tipifarnib; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota

Conditions: Rectal Cancer, Breast Cancer, Lung Cancer
Interventions: Not listed
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 70 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
Interventions: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 8
States / cities: Duarte, California • Basking Ridge, New Jersey • Commack, New York + 5 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)
Interventions: Cabozantinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Small Cell Lung Cancer
Interventions: imatinib mesylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions: Carboplatin, Paclitaxel, Pevonedistat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Newport Beach, California • Washington D.C., District of Columbia + 4 more

Conditions: Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
Interventions: Pembrolizumab, TAK-676, Image-guided radiation therapy; Drug · Radiation
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Duarte, California • Chicago, Illinois • New York, New York + 2 more

Conditions: Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery; Biological · Other · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 43
States / cities: Duarte, California • Encinitas, California • Fresno, California + 25 more

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy; Biological · Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cyclophosphamide, DRibble vaccine, Imiquimod, GM-CSF, HPV vaccine; Drug · Biological
Lead sponsor: UbiVac; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New Orleans, Louisiana • Portland, Oregon

Conditions: Lung Cancer, Cancer of the Lung
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Creve Coeur, Missouri

Conditions: Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions: oCRH; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 70 Years
Enrollment: 1,387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Posterior Fossa Hemorrhage, Lung Cancer, Flank Pain, Urolithiasis, Focal Hepatic Necrosis
Interventions: Not listed
Lead sponsor: GE Healthcare; Industry
Eligibility: 30 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Durham, North Carolina • Miwaukee, Wisconsin

Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions: Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 36
States / cities: Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more

Conditions: Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions: WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique; Biological · Genetic · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: nicotine lozenge, nicotine patch; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Miami Beach, Florida • Augusta, Georgia + 7 more

Conditions: Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant, Mesothelin (Msln)
Interventions: Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin; Procedure · Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer

Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Cabozantinib in Advanced Solid Malignancies

Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Pilot Study of Model Based Iterative Reconstruction Using 64-Slice

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin